XEN and the Conjunctiva - To Open or Close? Ab externo with open conjunctiva may lead to improved success rates & IOP control compared to ab externo with closed conjunctiva at the expense of longer procedure time and greater 5-FU usage. #glaucoma https://t.co/CIBRWBRARG
We are pleased to announce that Dr. Cindy Hutnik, Chair/Chief of the Department of Ophthalmology, has been named the inaugural Marcel and Louise Brunette Research Chair in Ophthalmology.
https://t.co/J7yQLBfDGx
Had the privilege to try GONIO ready®️ from @oculussurgical in the OR with @ikekahmed. A Hand- free gonioscopy device that allows you to use both hands during angle surgery which provides better control and more consistent and safe way in performing MIGS
Femtosecond Laser Image Guided High-precision Trabeculotomydemonstrated a favorable safety profile, w/o laser related serious adverse events. Well defined channels were clearly visible at 24mo, indicating medium-term patency & durability. https://t.co/KUZsrw5rK6 #glaucoma#MIGS
Ab-Externo SIBS Microshunt w/ MMC - 3 year results are in! The microshunt adequately controlled IOP IN 56% without meds and 75% with meds. Only 15% required needling. #ophthalmology#glaucoma#Preserflo@JakeJames88@ikekahmed https://t.co/tM4HB4orJm
Glaucoma staging is now well-defined and based on ONH changes and perimetry. Anatomically narrow angles is now called "Primary Angle-Closure Suspect"
#ophthalmology#ophthotwitter#medtwitter
This just in: Congress has EXPANDED residency slots for only the second time in 25 years.
Congress has approved 200 additional residency slots for 2023. This is progress, but we still need a lot more. It’s projected we’ll be short 124,000 physicians by 2034.
Data: @AAMCtoday
Finished up my first week @MoranEyeCenter I've met the most incredible people and have learned so much more than I could've imagined. And just look at that view !!
Omlonti is the first FDA approved EP2 receptor agonist for glaucoma! New treatments bring new hopes and possibilities - plus it is nice to have @SantenUSA join in the fight against glaucoma (in addition to their support for Preserflo w @GlaukosCorp)!
Glaucoma Detectable 10 Years Prior to Its Clinical Manifestations
Study authors envision a process for more routine early screening of the general population, likely at five-year intervals.
https://t.co/KcQRDxTmqq
#retina#glaucoma#optometry
More than cosmetic: Preop severe prostaglandin-associated periorbitopathy (PAP) decreases the success rate of trabeculectomy. New study argues prostaglandin eye drops should be switched or stopped before PAP becomes severe. #glaucoma#ophthalmology https://t.co/aNsHCGxTAU
Yamane technique haptic erosion: clinical features, treatment options, and visual outcomes in a retrospective multicenter case series: https://t.co/FVYzDy6due #ophthalmology#retina#cornea
IRIS Registry Analysis: Reop rates following #MIGS were substantially lower when performed w/ phaco. Black patients, eyes with mod-severe #glaucoma, & high baseline IOP were a/w higher risk of reop. #ophthalmology@DrZebardast https://t.co/PxzledLnaD
Medical data used to train AI algorithms lacks diversity. Most data comes from a few hospitals in the US.
We are launching an initiative to bring you diverse medical image datasets from across the globe: MAIDA.
Here's what MAIDA is about.
🧵
https://t.co/jvfIh6bkPK
Our Ike Ahmed, MD, and Jeff Pettey, MD, MBA attending the first day of @GlaucomaToday's Interventional Glaucoma Consortium held in Salt Lake City at the John A. Moran Eye Center.
Thank you @aao_ophth for recognizing our poster on risk of intraocular inflammation following anti-VEGF therapy as one of the best posters of the American Academy of Ophthalmology 2022 Meeting! Truly honoured.
Full paper here: https://t.co/jOaD45b5WA
#research#Ophthalmology